Endomag’s Magseed marker granted a CE mark

A CE mark has been granted to Endomag’s Magseed marker, previously granted to mark and help eliminate breast tumours through implementing it into patients.

Due to the grant, the device can now mark uncertain lymph nodes in patients before they undergo chemotherapy, thus allowing physicians to perform specialised surgery if their cancer has developed.

Consultant oncoplastic breast surgeon at Wythenshawe Hospital, Manchester University NHS Foundation Trust, James Harvey, stated: “When it comes to marking lymph nodes in patients receiving neoadjuvant chemotherapy there are very few options; wires are notoriously difficult to place and can easily migrate, often resulting in multiple lymph nodes being removed but not the one you necessarily wanted to take. It’s a huge step forward that we can now use the Magseed marker to mark lymph nodes across Europe, which will allow us to offer our patients more targeted surgery and accurate staging.”

Endomag’s CEO, Eric Mayes, stated: “Ever since we launched the Magseed marker we have been asked by European physicians if they can use it to mark a variety of different cancer sites in the body, which also require a longer implantation than the thirty days we had in Europe. We received this expanded indication from the FDA last year and I’m delighted that Endomag is the first to offer this same level of targeted treatment to European cancer patients.”

An Associate Professor in the Department of Breast Surgical Oncology at Houston’s University of Texas MD Anderson Cancer Centre, Dr Abigail Caudle, stated: “We have been using Magseed for 2 years and have performed over 1000 surgeries with the technology. The ability to mark lymph nodes and ensure we remove the cancerous node to examine them closely is a huge advantage for patients because we spare them extensive and unnecessary axillary surgery.”